Alzinova will publish the following financial reports in 2025:

• Year-end report 2024, 27 February 2025
• Interim report for the first quarter 2025, 15 May 2025
• Half-year report for 2025, 21 August 2025
• Interim report for the third quarter 2025, 13 November 2025
• Year-end Report 2025, 26 February 2026

The annual report for 2024 will be published on April 24, 2025. Alzinova's Annual General Meeting will be held on 28 May 2025. You can find Alzinova's financial calendar on our website alzinova.com (https://www.alzinova.com/investors/financial-calendar/).

For more information, please contact:
Tord Labuda, CEO
E-mail: tord.labuda@alzinova.com

Please note that this is an English translation of a press release written in Swedish by Alzinova AB (publ), in the event of any inaccuracies, the Swedish version applies.

About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com